Biotech Values

[bladerunner1717]

Peter,

Dr. Ron Garren says that triple negative breast cancer is more prevalent that HER+ breast cancer and puts the incidence at around 25% of all breast cancers. The SeekingAlpha author has it pegged at 15%. Which number do you think is more accurate?

If CLDX could find a Euro partner for Rindo--not likely, it seems--would you be more inclined to invest?

Could you imagine the breast cancer drug making a big splash at ASCO?

Do you see any value in the early clinical stage CDX 1127, an antibody that targets CD27?


Bladerunner


P.S. Do you have any new opinion on XNPT?